Citations

Clear

4801 citation(s) found for "Yu, Jennifer".

Randomized phase 2 study of gemcitabine with or without ATR inhibitor berzosertib in platinum-resistant ovarian cancer: Final overall survival (OS) and biomarker analyses.
Konstantinopoulos, Panagiotis A. , Lee, Elizabeth Katherine, Cheng, Su–Chun, Hendrickson, Andrea E. Wahner , Kochupurakkal, Bose , Kohn, Elise C. , Stover, Elizabeth H. , Curtis, Jennifer, Sawyer, Hannah , Polak, Madeline , D’Andrea, Alan D. , Matulonis, Ursula A. , Konstantinopoulos, Panagiotis A , D'Andrea, Alan , Lee, Elizabeth Katherine , Costa, Alexandre André Balieiro Anastácio da , Gulhan, D. , Kolin, David L. , Liu, Joyce F. , Chowdhury, Dipanjan , Färkkilä, Anniina , Shapiro, Geoffrey I.

Mayo Clinic

Journal of Clinical Oncology | June 4, 2023 | Volume: 41 | Issue: 16_suppl | Pages: 5512-5512

10.1200/jco.2023.41.16_suppl.5512 Get It

5512 Background: The multicenter, open-label, randomized phase 2 NCI-9944 study (NCT02595892) demonstrated that addition of ATR inhibitor (ATRi) berzosertib to gemcitabine increased progression-free survival (PFS) compared to gemcitabine alone (HR = 0.57, one-sided log-rank p = 0.044, which met the one-sided significance level of 0.1 used for sample size calculation). Final overall survival (OS) and corresponding biomarker analyses are reported here. Methods: Patients (pts) with platinum-resistant high-grade serous ovarian cancer and unlimited previous lines of cytotoxic therapy in the platinum-sensitive setting but no more than one line of cytotoxic therapy in the platinum-resistant setting, were randomized 1:1 to gemcitabine/berzosertib versus gemcitabine alone. Randomization was stratified based on platinum free interval (PFI), PFI≤3 months versus > 3 months. Crossover from gemcitabine to gemcitabine/berzosertib was allowed upon disease progression by RECIST 1.1. OS was a secondary endpoint while preplanned exploratory correlative studies included assessment of DNA repair pathways and replication stress (RS) alterations by targeted gene sequencing and/or immunohistochemistry (IHC). Results: Seventy pts were randomly assigned to treatment with gemcitabine/berzosertib (34 pts) or gemcitabine alone (36 pts); 15 pts crossed over from gemcitabine to gemcitabine/berzosertib. At the final OS analysis (92.9% maturity), median follow-up was 53.2 weeks in the gemcitabine/berzosertib and 43 weeks in the gemcitabine alone groups. Median OS in the intent-to-treat (ITT) population was 59.4 weeks in the gemcitabine/berzosertib group versus 43.0 weeks in the gemcitabine alone group (HR 0.79, 90% CI 0.52-1.2, one-sided p = 0.18). However, when patients who crossed over to gemcitabine/berzosertib were excluded from analysis, a significant OS benefit was observed with gemcitabine/berzosertib (HR 0.60, 90%CI 0.37−0.97); HR was 0.26 (90% CI 0.1−0.7) in pts with PFI≤3 months and 0.89 (90%CI 0.50−1.59) in pts with PFI > 3 months. Furthermore, significant OS benefit was observed in pts with RS-low tumors (HR 0.39, 90%CI 0.17−0.91, defined as tumors harboring no genomic RS alterations related to loss of RB pathway regulation and/or oncogene-induced RS) but not in pts with RS-high tumors (HR 0.74, 90%CI 0.35−1.56). Additional targeted gene sequencing and IHC analyses as well as analyses adjusting for patient crossover will be reported at the meeting. Conclusions: In the ITT population, gemcitabine/berzosertib did not significantly improve OS versus gemcitabine alone. Pts with PFI≤3 months and pts with RS-low tumors may derive a survival advantage from addition of berzosertib to gemcitabine in the platinum-resistant setting. Clinical trial information: NCT02595892 .
Survival outcomes in pediatric patients with metastatic Ewing sarcoma who achieve a rapid complete response of pulmonary metastases.
Huang, Lynn Y.L., Craig, Brian T. , Piché, Nelson , Lovvorn, Harold N. , Petroze, Robin T. , Rich, Barrie S. , Seemann, Natashia M. , Roach, Jonathan P. , Coakley, Brian A. , Grant, Christa N. , Bergus, Katherine , Bergus, Katherine C , Reiter, Audra J. , Talbot, Lindsay J , Aldrink, Jennifer H. , Polites, Stephanie F. , Dasgupta, Roshni , Malek, Marcus M. , Le, Hau D. , Kastenberg, Zachary J. , Tracy, Elisabeth T. , Lautz, Timothy B.

Mayo Clinic

Journal of Clinical Oncology | June 4, 2023 | Volume: 41 | Issue: 16_suppl | Pages: 11535-11535

10.1200/jco.2023.41.16_suppl.11535 Get It

11535 Background: Twenty-five percent of patients with Ewing Sarcoma (EWS) have metastatic disease at diagnosis, most commonly in the lungs. Our objectives were to compare overall (OS) and pulmonary disease-free survival (PDFS) between patients with metastatic EWS at diagnosis who achieve rapid complete response (RCR), defined as radiographic resolution of all pulmonary nodules at the end of induction chemotherapy, and those with residual pulmonary nodules after induction chemotherapy (non-RCR). Methods: This multi-center, retrospective cohort study included children under 20 years of age with metastatic EWS treated from 2007-2020 at 19 institutions participating in the Pediatric Surgical Oncology Research Collaborative. Chi-square tests were conducted for differences among groups, and p < 0.05 was considered significant. Kaplan-Meier curves were generated for OS and PDFS. Cox regression was performed for OS, controlling for whole lung irradiation (WLI), extrapulmonary metastases, and age. Results: Among 153 patients with metastatic EWS at diagnosis, 61 (40%) achieved RCR, and 87 (57%) did not (5 unknown). The median number of pulmonary nodules was 3.5 in the RCR vs 5 in the non-RCR groups (p = 0.02), while bilateral disease was present in 44 (72%) RCR vs 75 (86%) non-RCR patients (p = 0.03). Pulmonary relapse occurred in 58 (38%) patients, including 18 (29%) in the RCR and 36 (41%) in the non-RCR groups (p = 0.14). Factors associated with pulmonary relapse in the univariate analysis include median age [15 years (IQR: 12-17) with pulmonary relapse vs 12 years (IQR: 9-16) without (p = 0.03)] and extrapulmonary metastases at diagnosis [24 (41%) patients with pulmonary relapse vs 26 (27%) patients without pulmonary relapse (p = 0.05)]. WLI was performed in 100 patients and was not associated with a reduction in pulmonary relapse (p = 0.93). Complete surgical clearance of pulmonary disease was attempted in 29 (19%) patients, including 17 of the patients who met the criteria for RCR. On Kaplan-Meier analyses, 5-year PDFS did not significantly differ based on RCR (67%) vs. non-RCR (53%, p = 0.13), or WLI (61%) vs. no WLI (54%, p = 0.32). However, 5-year OS did vary significantly between patients with RCR and WLI (85%), RCR without WLI (55%), non-RCR with WLI (60%), and non-RCR without WLI (25%; p < 0.01). In Cox regression analysis, RCR was associated with improved OS after controlling for WLI, extrapulmonary metastases, and patient age (HR 0.51, p = 0.03). Conclusions: Patients with EWS who had pulmonary metastases at diagnosis had improved OS if they achieved RCR and received WLI, despite having no significant differences in rates of pulmonary relapse. Further research is needed to determine whether clearance of pulmonary disease achieved through surgical metastasectomy provides a comparable survival benefit and if any subsets of patients have a reduced risk of pulmonary relapse after resection.
Human Trafficking Education: A Pilot Study of Integration into Medical School Curriculum
Das, Devika , Talbott, Jennifer , Dutcher, Jordan S., Lim, Elisabeth S. , Vegunta, Suneela , David, Paru S., Das, Devika , Talbott, Jennifer Mv, Lim, Elisabeth, Talbott, Jennifer M V , Dutcher, Jordan S. , Buras, Matthew , Kling, Juliana M.

Mayo Clinic

Journal of Medical Education and Curricular Development | June 2, 2023 | Volume: 10 | Issue: No issue available | Pages: No page available

10.1177/23821205231164088 | PMID 37324053 Get It

OBJECTIVES Few medical schools incorporate formal education on human trafficking (HT) and sex trafficking (ST) into their curriculum. Our objective was to develop, implement, and evaluate education on HT and ST in the first-year medical student curriculum. METHODS The curriculum included a standardized patient (SP) experience and lecture. As part of their mandatory sexual health course, students interviewed an SP who presented with red flags for ST and then participated in a discussion led by a physician-facilitator in an observed small group setting. A multiple-choice survey to assess knowledge about HT and ST was developed and administered to students before and after the SP interview. RESULTS Of the 50 first-year medical students, 29 (58%) participated in the survey. Compared with the students’ baseline scores (according to the percentage of correct responses), scores after the educational intervention showed a significant increase in percentage correct on questions related to trafficking definition and scope (elder care, P = .01; landscaping, P = .03); victim identification ( P < .001); referral to services ( P < .001); legal issues ( P = .01); and security ( P < .001). On the basis of the feedback, a 2-hour lecture, which was adapted from the American Medical Women's Association–Physicians Against the Trafficking of Humans “Learn to Identify and Fight Trafficking” training, was presented the next year to all first-year medical students as part of their longitudinal clinical skills course and before the SP case. Curriculum objectives included learning trafficking definitions, victim/survivor identification, intersections with health care, the local impact of HT, and available resources. CONCLUSION This curriculum fulfills course objectives and could be replicated at other institutions. Further evaluation of this pilot curriculum is necessary to evaluate its effectiveness.
Management and Outcomes of Wilms Tumor With Suprarenal Intravascular Extension
Naik‐Mathuria, Bindi , Dasgupta, Roshni , Short, Scott S. , Lovvorn, Harold N. , Newman, Erica, Rich, Barrie S. , Piché, Nelson , Glick, Richard D. , Petroze, Robin T. , Polites, Stephanie F. , Alore, Elizabeth , Sutthatarn, Pattamon , Wong‐Michalak, Shannon , Romao, Rodrigo , Al‐Hadidi, Ameer , Marquart, John , Gainer, Hailey, Johnson, Mike, Boehmer, Chloé , Rinehardt, Hannah , Seemann, Natashia M. , Davidson, Jacob , Polcz, Valerie E., Lund, Sarah , McKay, Katlyn G. , Correa, Hernán , Lund, Sarah B, Dasgupta, Roshni , Utria, Alan Fremder , Ehrlich, Peter F. , Aldrink, Jennifer H. , Murphy, Andrew J. , Lautz, Timothy B. , Kim, Eugene S. , Lal, Dave R. , Kastenberg, Zachary J. , Malek, Marcus M. , Whitlock, Richard S. , Chen, Stephanie , Rubalcava, Nathan S. , Gainer, Hailey, Rothstein, David H.

Mayo Clinic

Annals of Surgery | June 2, 2023 | Volume: 279 | Issue: 3 | Pages: 528-535

10.1097/sla.0000000000005921 | PMID 37264925 Get It

Objective: The purpose of this study was to describe management and outcomes from a contemporary cohort of children with Wilms tumor complicated by inferior vena caval thrombus. Background: The largest series of these patients was published almost 2 decades ago. Since then, neoadjuvant chemotherapy has been commonly used to manage these patients, and outcomes have not been reported. Methods: Retrospective review of 19 North American centers between 2009 and 2019. Patient and disease characteristics, management, and outcomes were investigated and analyzed. Results: Of 124 patients, 81% had favorable histology (FH), and 52% were stage IV. IVC thrombus level was infrahepatic in 53 (43%), intrahepatic in 32 (26%), suprahepatic in 14 (11%), and cardiac in 24 (19%). Neoadjuvant chemotherapy using a 3-drug regimen was administered in 82% and postresection radiation in 90%. Thrombus level regression was 45% overall, with suprahepatic level showing the best response (62%). Cardiopulmonary bypass (CPB) was potentially avoided in 67%. The perioperative complication rate was significantly lower after neoadjuvant chemotherapy [(25%) vs upfront surgery (55%); P=0.005]. CPB was not associated with higher complications [CPB (50%) vs no CPB (27%); P=0.08]. Two-year event-free survival was 93% and overall survival was 96%, higher in FH cases (FH 98% vs unfavorable histology/anaplastic 82%; P=0.73). Neither incomplete resection nor viable thrombus cells affected event-free survival or overall survival. Conclusions: Multimodal therapy resulted in excellent outcomes, even with advanced-stage disease and cardiac extension. Neoadjuvant chemotherapy decreased the need for CPB to facilitate resection. Complete thrombectomy may not always be necessary.
Radiologically Inserted Gastrostomy Tube Placement Guided by the Assessment and Primary Palliative Care Provided by an Amyotrophic Lateral Sclerosis Multidisciplinary Clinic: A Single-Arm Retrospective Clinical Study
Parra‐Cantu, Carolina , Martinez‐Thompson, Jennifer M. , Linch, Forrest , Chou, Claudia Z., Pattinson, Adele K., Staff, Nathan P. , Neisen, Melissa , Linch, Forrest B , Neisen, Melissa , Staff, Nathan P , Welch, Tasha L.

Mayo Clinic

American Journal of Hospice and Palliative Medicine® | June 2, 2023 | Volume: 41 | Issue: 5 | Pages: 516-526

10.1177/10499091231180553 | PMID 37266922 Get It

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease with a median survival of about 3 years. An ALS multidisciplinary team can provide primary palliative care and improve outcomes and quality of life for patients. Feeding tube insertion may be considered for patients with significant weight loss, or respiratory insufficiency. While radiologically inserted gastrostomy (RIG) tube placement may be an option, further studies are required to determine its best timing and appropriateness. This study’s objectives were to evaluate the feasibility and outcomes of RIG tube placement in ALS patients over a 90-day follow-up period through the assessment and primary palliative care provided by the multidisciplinary team. This retrospective study reviewed the placement of 16 or 18 French RIG-tube without intubation or endoscopy for 36 ALS patients at a single center between April 2019 and December 2021. Measures included ALS Functional Rating Scale-Revised (ALSFRS-R) scores to determine the ALS stage. Demographic, clinical, procedural, and follow-up data were reviewed. Results showed that the RIG tube placement had a low rate of minor adverse events (11%) and no major procedure-related adverse events. The mean ALSFRS-R score at the time of procedure in subjects who died within 90 days was lower than of those alive beyond 90 days ( P = .04). This study found that RIG-tube placement is a safe and effective way to manage dysphagia in ALS patients and highlights the importance of educating members of the multidisciplinary clinic in palliative care principles to determine the appropriateness of RIG tube placement.
Development of a Skin-Directed Scoring System for Stevens-Johnson Syndrome and Epidermal Necrolysis
Waters, Margo , Dobry, Allison S. , Le, Stephanie T. , Shinkai, Kanade , Beachkofsky, Thomas M. , Davis, Mark D.P. , Markova, Alina , Pasieka, Helena B. , Rosenbach, Misha , Seminario‐Vidal, Lucia , Trinidad, John , Altman, Emily , Arakaki, Ryan, Ardern‐Jones, Michael R. , Bridges, Alina G. , Cardones, Adela R. , Chen, Jennifer K. , Chen, Steven T. , Cheng, Kyle , Harp, Joanna, King, Brett , Lowenstein, Eve J. , Luxenberg, Erin, Mancuso, Jennifer , Mauskar, Melissa , Milam, Philip , Nelson, Caroline A. , Nguyen, Cuong V. , Nutan, Fnu, Patel, Tejesh , Rahnama‐Moghadam, Sahand , Rekhtman, Sergey , Rojek, Nathan W. , Sarihan, Mansi, Shaigany, Sheila , Sharma, Timmie R. , Shearer, Sabrina M, Shields, Bridget E. , Strowd, Lindsay C. , Tartar, Danielle , Walls, Andrew C., Ziemer, Carolyn, Kaffenberger, Benjamin H. , Nguyen, C V , Seminario-Vidal, L , Kaffenberger, B , Dominguez, Arturo Ricardo , Kroshinsky, Daniela , Micheletti, Robert , Mostaghimi, Arash , Albrecht, Joerg , Chadha, Angad , Daveluy, Steven , DeNiro, Katherine L. , Keller, Jesse Joel , Korman, Abraham Moris , Motaparthi, Kiran , Ortega‐Loayza, Alex G. , Shaigany, Sheila , Thomas, Cristina , Wanat, Karolyn A. , Walls, Andrew F. , Zaba, Lisa C. , Maverakis, Emanual Michael

Mayo Clinic

JAMA Dermatology | May 31, 2023 | Volume: 159 | Issue: 7 | Pages: 772

10.1001/jamadermatol.2023.1347 | PMID 37256599 Get It

Importance Scoring systems for Stevens-Johnson syndrome and epidermal necrolysis (EN) only estimate patient prognosis and are weighted toward comorbidities and systemic features; morphologic terminology for EN lesions is inconsistent. Objectives To establish consensus among expert dermatologists on EN terminology, morphologic progression, and most-affected sites, and to build a framework for developing a skin-directed scoring system for EN. Evidence Review A Delphi consensus using the RAND/UCLA appropriateness criteria was initiated with a core group from the Society of Dermatology Hospitalists to establish agreement on the optimal design for an EN cutaneous scoring instrument, terminology, morphologic traits, and sites of involvement. Findings In round 1, the 54 participating dermatology hospitalists reached consensus on all 49 statements (30 appropriate, 3 inappropriate, 16 uncertain). In round 2, they agreed on another 15 statements (8 appropriate, 7 uncertain). There was consistent agreement on the need for a skin-specific instrument; on the most-often affected skin sites (head and neck, chest, upper back, ocular mucosa, oral mucosa); and that blanching erythema, dusky erythema, targetoid erythema, vesicles/bullae, desquamation, and erosions comprise the morphologic traits of EN and can be consistently differentiated. Conclusions and Relevance This consensus exercise confirmed the need for an EN skin-directed scoring system, nomenclature, and differentiation of specific morphologic traits, and identified the sites most affected. It also established a baseline consensus for a standardized EN instrument with consistent terminology.
Abstract 5768: Genetic screening in a tertiary medical center identifies carriers of cancer predisposition diseases that would be missed by clinical guidelines
Gay, E. Greer , Samadder, N. Jewel , Bublitz, Michelle L. , Peterson, Melanie M., Wilson, Tammy A., Bandel, Lorelei A. , Armasu, Sebastian M. , Ferber, Matthew J. , Klee, Eric W. , Kruisselbrink, Teresa , Egan, Jan B. , Kemppainen, Jennifer L., Bidwell, Jessa S., McAllister, Tammy M., Walker, T'Nita S., Lindpere, Vanda , Golafshar, Michael A. , Klint, Margaret, Bolster, Jolene M. Summer, Bidwell, Jessa , Golafshar, Michael , Bidwell, Jessa S , Lindpere, Vanda , Gay, Emily, Peterson, Melanie M., Vierkant, Robert A. , Larson, Nicholas B. , Curry, Timothy B. , Anderson, Jennifer L., Kunze, Katie L. , Presutti, R. John , Bobo, William V. , Sekulic, Aleksander , Willman, Cheryl L. , Lazaridis, Konstantinos N.

Mayo Clinic

Cancer Research | May 30, 2023 | Volume: 83 | Issue: 7_Supplement | Pages: 5768-5768

10.1158/1538-7445.am2023-5768 Get It

Abstract Two inherited autosomal dominant cancer predisposition conditions - BRCA related hereditary breast and ovarian cancer (HBOC) and Lynch syndrome (LS) - are termed Centers for Disease Control and Prevention Tier 1 (CDCT1) genetic conditions, for which early identification and intervention have a positive impact on public health. Selection of individuals for genetic testing for these conditions is based on personal and family history. The goal of this study was to evaluate whether screening in a tertiary medical center using exome sequencing could efficiently identify carriers of HBOC and LS and to determine the frequency of incremental carriers identified outside of traditional clinical practice guidelines. Participants from three geographically diverse Mayo Clinic practices in the USA (Rochester MN, Phoenix AZ, Jacksonville FL) consented to clinical “Exome+” sequencing (Helix, San Mateo, CA; Mayo GeneGuide, Rochester, MN) in the TAPESTRY study (NCT05212428), which links sequencing data with electronic health records and the return of CDCT1 genetic findings. For this study we focused on two inherited cancer predisposition conditions: BRCA-related HBOC (BRCA1 and BRCA2) and LS (MLH1, MSH2, MSH6, PMS2 and EPCAM). Detailed chart review to collect demographic information, personal and family history, and assessment of clinical practice guidelines for genetic evaluation (National Cancer Control Network 2021). To date, 44,306 patients have enrolled and sequenced in TAPESTRY. Annotation and interpretation of all variants in 7 genes for HBOC and LS resulted in identification of 550 carriers (prevalence 1.24%) which included 387 with HBOC (27.2% BRCA1, 42.8% BRCA2) and 163 with LS (12.3% MSH6, 8.8% PMS2, 4.5% MLH1, 3.8% MSH2 and 0.2% EPCAM). Demographics of the cohort included: 62.7% female, mean age 55.2 years, non-white race 9.6% and 3.8% Hispanic/Latino ethnicity. A personal history of cancer was present in 46.4% of test positive patients, including 22.5% of HBOC patients with breast or ovarian cancer and 20.9% of LS patients with colorectal or uterine cancer. More than half of the patients (52.1%) were newly diagnosed with HBOC and LS based on the results of this study. Overall, 39.2% of HBOC/LS carriers identified through Exome+ sequencing did not satisfy NCCN criteria for genetic evaluation, this was higher for LS (56.2%) compared to HBOC (32%). Amongst those newly diagnosed with HBOC/LS (n=286), NCCN criteria were not satisfied in 60% of cases (78% for LS and 51% for HBOC). Of the pathogenic germline variant carriers who met NCCN guidelines for testing, 34.2% were not aware of their diagnosis prior to participation in this study. Our results emphasize the need for wide genomic screening for CDCT1 cancer predisposition syndromes. Such screening could identify at-risk carriers of HBOC and LS, who would not otherwise be identified through clinical practice guidelines. Citation Format: Emily Gay, Niloy Jewel Samadder, Michelle L. Bublitz, Melanie M. Peterson, Tammy A. Wilson, Lorelei A. Bandel, Sebastian M. Armasu, Robert A. Vierkant, Matthew J. Ferber, Eric W. Klee, Nicholas B. Larson, Teresa M. Kruisselbrink, Timothy B. Curry, Jan B. Egan, Jennifer L. Kemppainen, Jessa S. Bidwell, Jennifer L. Anderson, Tammy M. McAllister, T'Nita S. Walker, Katie L. Kunze, Vanda Lindpere, Michael A. Golafshar, Margaret Klint, Richard J. Presutti, William V. Bobo, Aleksander Sekulic, Jolene M. Summer Bolster, Cheryl L. Willman, Konstantinos N. Lazaridis. Genetic screening in a tertiary medical center identifies carriers of cancer predisposition diseases that would be missed by clinical guidelines [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5768.
A Genetic Locus within the FMN1/GREM1 Gene Region Interacts with Body Mass Index in Colorectal Cancer Risk
Aglago, Elom K. , Kim, Andre E. , Lin, Yi , Qu, Conghui , Evangelou, Marina , Yu, Ren , Morrison, John L. , Albanes, Demetrius , Arndt, Volker , Barry, Elizabeth L. , Baurley, James W. , Berndt, Sonja I. , Bishop, D. Timothy , Bouras, Emmanouil , Brenner, Hermann , Casey, Graham , Chang‐Claude, Jenny , Díez‐Obrero, Virginia , Figueiredo, Jane C. , Gallinger, Steven , Gruber, Stephen B. , Gsur, Andrea , Harlid, Sophia , Harrison, Tabitha A. , Hoffmeister, Michael , Huyghe, Jeroen R. , Jordahl, Kristina M. , Joshi, Amit D. , Kundaje, Anshul , Li, Li , Mandic, Marko , Obón‐Santacana, Mireia , Nan, Hongmei , Nassir, Rami , Ose, Jennifer , Pai, Rish K. , Papadimitriou, Nikos , Prentice, Ross L. , Scacheri, Peter C. , Schmit, Stephanie L. , Slattery, Martha L. , Thibodeau, Stephen N. , Thomas, Duncan C. , Duijnhoven, Fränzel J.B. van , Guelpen, Bethany Van , Visvanathan, Kala , Vodička, Pavel , White, Emily , Woods, Michael O. , Wu, Anna H. , Zemlianskaia, Natalia , Gauderman, W. James , Peters, Ulrike , Kim, Andre E , Ren, Yu , Morrison, John L , Bien, Stephanie A , Bishop, D Timothy , Bouras, Emmanouil , Brenner, Hermann , Buchanan, Daniel D , Budiarto, Arif , Carreras-Torres, Robert , Casey, Graham , Cenggoro, Tjeng Wawan , Chan, Andrew T , Chang-Claude, Jenny , Chen, Xuechen , Conti, David V , Devall, Matthew A M , Diez-Obrero, Virginia , Dimou, Niki , Drew, David A , Figueiredo, Jane C , Gallinger, Steven , Giles, Graham G , Gruber, Stephen B , Gsur, Andrea , Gunter, Marc J , Hampel, Heather , Harlid, Sophia , Hidaka, Akihisa , Harrison, Tabitha A , Hoffmeister, Michael , Huyghe, Jeroen R , Jenkins, Mark A , Jordahl, Kristina M , Joshi, Amit D , Kawaguchi, Eric , Keku, Temitope O , Kundaje, Anshul , Larsson, Susanna C , Marchand, Loïc Le , Lewinger, Juan Pablo , Li, Li , Lynch, Brigid M , Mahesworo, Bharuno , Mandic, Marko , Obón-Santacana, Mireia , Moreno, Victor , Murphy, Neil , Nan, Hongmei , Nassir, Rami , Newcomb, Polly A. , Ogino, Shuji , Ose, Jennifer , Pai, R K , Palmer, Julie R , Papadimitriou, Nikos , Pardamean, Bens , Peoples, Anita R , Platz, Elizabeth A. , Potter, John D , Prentice, Ross L , Rennert, Gad , Ruiz-Narvaez, Edward , Sakoda, Lori C , Scacheri, Peter C , Schmit, Stephanie L , Schoen, Robert E , Shcherbina, Anna , Slattery, Martha L , Stern, Mariana Carla , Su, Yu-Ru , Tangen, Catherine M , Thibodeau, Stephen N , Thomas, Duncan C , Tian, Yu , Ulrich, Cornelia M , van Duijnhoven, Fränzel J B , Van Guelpen, Bethany , Visvanathan, Kala , Vodicka, Pavel , Wang, Jun , White, Emily , Wolk, Alicja , Woods, Michael O , Wu, Anna H. , Zemlianskaia, Natalia , Hsu, Li , Gauderman, W James , Peters, Ulrike , Tsilidis, Konstantinos K , Campbell, Peter T , Arndt, Volker , Aglago, Elom K , Albanes, Demetrius , Qu, Conghui , Bien, Stephanie A. , Buchanan, Daniel D. , Carreras‐Torres, Robert , Chan, Andrew T. , Conti, David V. , Dimou, Niki , Drew, David A. , Giles, Graham G. , Gunter, Marc J. , Hampel, Heather , Hidaka, Akihisa , Jenkins, Mark A. , Larsson, Susanna C. , Marchand, Loı̈c Le , Lewinger, Juan Pablo , Moreno, Vı́ctor , Murphy, Neil , Palmer, Julie R. , Pardamean, Bens , Potter, John D. , Rennert, Gad , Sakoda, Lori C. , Schoen, Robert E. , Shcherbina, Anna , Tangen, Catherine M. , Tian, Yu , Ulrich, Cornelia M. , Wolk, Alicja , Tsilidis, Konstantinos K. , Campbell, Peter T.

Mayo Clinic

Cancer Research | May 30, 2023 | Volume: 83 | Issue: 15 | Pages: 2572-2583

10.1158/0008-5472.can-22-3713 | PMID 37249599 Get It

Abstract Colorectal cancer risk can be impacted by genetic, environmental, and lifestyle factors, including diet and obesity. Gene-environment interactions (G × E) can provide biological insights into the effects of obesity on colorectal cancer risk. Here, we assessed potential genome-wide G × E interactions between body mass index (BMI) and common SNPs for colorectal cancer risk using data from 36,415 colorectal cancer cases and 48,451 controls from three international colorectal cancer consortia (CCFR, CORECT, and GECCO). The G × E tests included the conventional logistic regression using multiplicative terms (one degree of freedom, 1DF test), the two-step EDGE method, and the joint 3DF test, each of which is powerful for detecting G × E interactions under specific conditions. BMI was associated with higher colorectal cancer risk. The two-step approach revealed a statistically significant G×BMI interaction located within the Formin 1/Gremlin 1 (FMN1/GREM1) gene region (rs58349661). This SNP was also identified by the 3DF test, with a suggestive statistical significance in the 1DF test. Among participants with the CC genotype of rs58349661, overweight and obesity categories were associated with higher colorectal cancer risk, whereas null associations were observed across BMI categories in those with the TT genotype. Using data from three large international consortia, this study discovered a locus in the FMN1/GREM1 gene region that interacts with BMI on the association with colorectal cancer risk. Further studies should examine the potential mechanisms through which this locus modifies the etiologic link between obesity and colorectal cancer. Significance: This gene-environment interaction analysis revealed a genetic locus in FMN1/GREM1 that interacts with body mass index in colorectal cancer risk, suggesting potential implications for precision prevention strategies.
Beta intrusion during N2 sleep is negatively associated with nocturnal heart rate variability in healthy adults
Migliaccio, Gianna, Greenlund, Ian M. , Barkstrom, Elyse, Nicevski, Jennifer, Tikkanen, Anne, Carter, Jason , Barkstrom, Elyse, Bigalke, Jeremy A. , Carter, Jason

Mayo Clinic

Physiology | May 29, 2023 | Volume: 38 | Issue: S1 | Pages: No page available

10.1152/physiol.2023.38.s1.5731406 Get It

Increased cognitive hyperarousal is a proposed mechanism associated with clinical poor sleep including insomnia. An objective marker of nocturnal hyperarousal is high frequency electroencephalography during sleep, including increased beta frequency during stage two (N2) sleep. Acute and chronic poor sleep quality are associated with autonomic dysfunction, but little is known regarding the relationship between nocturnal beta frequency intrusion and nocturnal autonomic function. The purpose of this study was to explore the association between beta spectral power during stage two (N2) sleep and nocturnal heart rate variability (HRV) in healthy female and male adults. We hypothesized that heightened beta spectral power during N2 sleep would be associated with reduced nocturnal HRV. Twenty-four participants (12 males, 12 females; age, 25 ± 1 years; BMI 27 ± 1 kg/m2) underwent an 8-hour overnight sleep opportunity with continuous polysomnography and 5-lead electrocardiogram monitoring. Periods of 5 – 10 minutes of stable N2 sleep absent of cortical arousals, respiratory events, and limb movement-associated arousals were identified (one per cycle) for analysis. Periods from the first two cycles of N2 sleep from the full night were selected for analysis. Beta spectral power from the central and frontal regions and nocturnal HRV data were analyzed and averaged across each hemisphere. Time-domain HRV was quantified as the root mean squared of successive differences (RMSSD) and proportion of R-R intervals (RRI) varying by greater than 50 ms (pNN50). An inverse correlation was observed between central beta power and RRI (R= -0.473, p=0.019), pNN50 (R= -0.450, p=0.028), and RMSSD (R= -0.406, p=0.049). This was paralleled by a similar relationship between frontal beta and RRI (R= -0.487, p=0.016) and pNN50 (R= -0.423, p=0.039). Our results indicate a negative association between N2 beta power and nocturnal HRV measures. These findings suggest that nocturnal hyperarousal may be associated with poor cardiac autonomic function and has implications for individuals with insomnia in whom cognitive hyperarousal is frequently reported. Support is provided by the National Institutes of Health (AA-024892, U54GM115371; P20GM103474, 2TL1 TR002318). This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.